linjc16/ctgov huggingface dataset:
Stiripentol in Dravet Syndrome

Study Overview
=================
Brief Summary
-----------------
The patient has failed all other available agents and has intractable epilepsy due to Dravet Syndrome. Stiripentol is highly efficacious in Dravet Syndrome. The overall goals of therapy with Stiripentol are primarily to significantly reduce the frequency and severity of seizures.

Official Title
-----------------
Compassionate Use of Stiripentol in Intractable Epilepsy Due to Dravet Syndrome

Conditions
-----------------
Dravet Syndrome

Intervention / Treatment
-----------------
* Drug: stiripentol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Genetic diagnosis of Dravet syndrome with intractable seizures despite failing all available medications for seizures

Ages Eligible for Study
-----------------
Minimum Age: 11 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: stiripentol|Stiripentol up to 30 mg/kg/day to control seizures|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
treatment with stiripentol
Subclinical Hypothyroidism and Acute Anterior Myocardial Infarction: Is it Cardio-protective or Not?

Study Overview
=================
Brief Summary
-----------------
The study plans to investigate whether recovery of the heart function after acute anterior myocardial infarction is dependent upon improvement in thyroid gland functioning.

Conditions
-----------------
Heart Injuries

Intervention / Treatment
-----------------
* Other: Echo-cardiogram
* Other: Blood test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Have suffered anterior myocardial infarction Exclusion Criteria: Do not receive thyroid treatment No history of ischemic heart disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Anterior Myocardial Infarction<br>Patients who have suffered anterior myocardial infarction in our hospital | Other: Echo-cardiogram<br>* Patients will undergo echo-cardiogram to determine improvement in their heart function and this will be compared to thyroid function<br>Other: Blood test<br>* Blood test to determine thyroid function<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ejection Fraction Improvement | Improvement in ejection fraction as shown in echo-cardiogram | 40 days | 
| Improvement in thyroid function | Thyroid stimulating hormone (TSH) level will be normal. | 40 days |
Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Peyronie's Disease, ED, and Interstitial Cystitis

Study Overview
=================
Brief Summary
-----------------
This trial will study the safety and efficacy of intravenous and intracavernosal or interstitial delivery of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Peyronie's disease, erectile dysfunction , and Interstitial Cystitis

Detailed Description
-----------------
This patient funded trial aims to study the safety and efficacy of intravenous and intracavernosal or interstitial delivery of cultured allogeneic adult umbilical cord derived mesenchymal stem cells (UC-MSCs) for the treatment of Peyronie's disease, erectile dysfunction , and Interstitial Cystitis. The total dose will be 100 million cells. Patients will be evaluated within one month pre treatment and at 1, 6, 12, 24, 36, and 48 months post treatment for safety and efficacy.

Official Title
-----------------
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Peyronie's Disease, Erectile Dysfunction, and Interstitial Cystitis

Conditions
-----------------
Erectile Dysfunction, Peyronie's Disease, Interstitial Cystitis

Intervention / Treatment
-----------------
* Biological: AlloRx


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of Peyronie's Disease, erectile dysfunction, or Interstitial Cystitis Understanding and willingness to sign a written informed consent document Exclusion Criteria: Active infection Active cancer Chronic multisystem organ failure Pregnancy Clinically significant Abnormalities on pre-treatment laboratory evaluation Medical condition that would (based on the opinion of the investigator) compromise patient's safety. Continued drug abuse Pre-menopausal women not using contraception Previous organ transplant Hypersensitivity to sulfur
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Treatment Group (AlloRx)<br>intravenous and intracavernosal or interstitial delivery (total dose of 100 million cells) | Biological: AlloRx<br>* cultured allogeneic adult umbilical cord derived mesenchymal stem cells<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety (adverse events) | Clinical monitoring of possible adverse events or complications | Four year follow-up | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Erectile Dysfunction, Peyronie's Disease, stem cell treatment, Interstitial Cystitis
Randomized Controlled Trial to Compare Two Anti-scorpion Serums

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the efficiency and safety of the treatment against sting scorpion, using two serums, one elaborated by Birmex versus other commercial serum

Detailed Description
-----------------
We consider relevant conduct this study because the poisoning scorpion bite represents a public health problem. This is a randomized clinical trial, which included 120 subjects of both sexes aged 15 and 60 years old and residents of the state of Guanajuato, divided into 2 groups: 60 patients received antiscorpion serum of Birmex and 60 patients receive other commercial serum.

Official Title
-----------------
Randomized Controlled Trial to Evaluate Efficiency and Safety of the Polyvalent Antiscorpion Serum of Birmex Versus Other Commercial Serum

Conditions
-----------------
Scorpion Sting

Intervention / Treatment
-----------------
* Biological: serum antiscorpion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Sting scorpion Informed consent Age 15-60 Either sex Resident in study area Exclusion Criteria: Previous treatment with gammaglobulin Blood transfusion at any stage of life Sensitivity or intolerance to serums antiscorpion or horse products Pregnancy Some immunodeficiency

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: I<br>Patients 15 to 60 years with scorpion sting, will receive serum antiscorpion elaborated by Birmex | Biological: serum antiscorpion<br>* The dose may be required for the patient according to clinical manifestations and evolution<br>* Other names: anti-Scorpion venom Serum;|
| Experimental: II<br>Patients 15 to 60 years with scorpion sting, will receive other commercial serum antiscorpion (Alacramyn) | Biological: serum antiscorpion<br>* The dose may be required for the patient according to clinical manifestations and evolution<br>* Other names: anti-Scorpion venom Serum;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Resolution of signs and symptoms of scorpion envenomation |  | after treatment (expected average of 12 hrs) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluate the adverse events in every treated child |  | inmediately after treatment and until 5 days later |
The Influence of Mother Nutrition on Breast Milk Microbiome

Study Overview
=================
Brief Summary
-----------------
The research subject Health organizations around the world have determined that breastfeeding is the most critical source of nutrition for newborns in the first weeks and months of their lives. A mother's breast milk contains unique nutritious components and other nonnutritive elements that help promote healthy baby growth and development (1, 2). Recent studies show that a mother's breast milk contains components that vary from each specimen. There are great evidences that maternal and environmental factors have a strong influence on the composition of breast milk. Fatty acids, the second most common component found in breast milk, show extreme sensitivity to maternal nutrition (3, 4). Latest studies show that breast milk also contains bacterial communities that may have health implications of newborn. The structure of these bacterial communities also varied greatly between subjects (5) . In the research, we propose to investigate the connection between maternal nutrition, different fatty acids and their role in the growth and development of bacterial populations existing in breast milk.

Official Title
-----------------
The Influence of Mother Nutrition on the Composition of Fatty Acid, Oligosacharides and Its Effect on Breast Milk Microbiome

Conditions
-----------------
Breast Milk, Composition, Microbiome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:Healthy lactating women, breast feeding for the first 3 months after delivery Exclusion Criteria: No compliance, sickness, drug consumption -
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in breast milk composition in relation to nutritional intake |  | 3 months |
Investigation of Subsequent and Co-infections Associated With SARS-CoV-2 (COVID-19)

Study Overview
=================
Brief Summary
-----------------
Multicenter retrospective chart review of patients admitted to any of the four Methodist Health System hospitals

Detailed Description
-----------------
Multicenter retrospective chart review of patients admitted to any of the four Methodist Health System hospitals (Methodist Richardson, Methodist Mansfield, Methodist Charlton, or Methodist Dallas) between February 1 and April 30, 2020. All study center utilize Epic ® electronic health record (Verona, Wisconsin; www.epic.com) for which all data will be extracted from.

Official Title
-----------------
Investigation of Subsequent and Co-infections Associated With SARS-CoV-2 (COVID-19)

Conditions
-----------------
COVID-19

Intervention / Treatment
-----------------
* Other: Observational


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients admitted to Methodist Richardson, Methodist Mansfield, Methodist Charlton, or Methodist Dallas Medical Centers between February 1, 2020 and April 30, 2020 >18 years old Positive SARS-CoV-2 (COVID-19) PCR test Exclusion Criteria: Outpatient or emergency department visit Not admitted to an inpatient or observation status for >24 hours

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Retrospective Cohort<br>Patients admitted to Methodist Richardson, Methodist Mansfield, Methodist Charlton, or Methodist Dallas Medical Centers between February 1, 2020 and April 30, 2020 with positive COVID-19 PCR test. | Other: Observational<br>* Observational<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of subsequent and co-infections | Prevalence of subsequent and co-infections | Feb 2020 - April 2020 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| In-hospital mortality | In-hospital mortality | Feb 2020 - April 2020 | 
| Hospital length of stay (LOS) | Hospital length of stay (LOS) | Feb 2020 - April 2020 |
Ultrasound Guided Transversus Abdominis Plane (TAP) Block for Postoperative Analgesia After Laparoscopic Colonic Resection

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether the transversus abdominis plane (TAP) blocks are effective in postoperative pain control of adult patients undergoing laparoscopic colectomy.

Conditions
-----------------
Laparoscopic Colecctomy

Intervention / Treatment
-----------------
* Procedure: Ultrasound Guided Transversus Abdominis Plane (TAP) Block
* Drug: bupivacaine
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: aged 20 80 undergoing laparoscopic colectomy Exclusion Criteria: allergic history to local anesthesitcs tolerance to opioid cannot use IV-PCA previous abdominal surgery intestinal obstruction emergency

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: an odd numbered patients<br>TAP block with local anesthetics | Procedure: Ultrasound Guided Transversus Abdominis Plane (TAP) Block<br>* Ultrasound Guided Transversus Abdominis Plane (TAP) Block<br>Drug: bupivacaine<br>* 0.25 bupivacaine 30ml (15ml on each side)<br>|
| Placebo Comparator: an even numbered patients<br>TAP block without local anesthetics | Procedure: Ultrasound Guided Transversus Abdominis Plane (TAP) Block<br>* Ultrasound Guided Transversus Abdominis Plane (TAP) Block<br>Drug: Placebo<br>* placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pain score during cough | pain score during cough at 24 hours after TAP block (using visual analog scale) | 24hr after TAP block | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pain score during bed rest and ambulation at ward, dosage of used opioid, nausea score, sedation score, days of hospitalization, start day of diet, reinsertion rate of urinary catheter, satisfaction measurement of pain control, life of quality |  | 24hr, 48hr, 72hr after TAP block |
Access to Sperm Donation for Female Couples and Unmarried Women

Study Overview
=================
Brief Summary
-----------------
The Bioethics Law of August 2, 2021 now authorizes, in addition to heterosexual couples, access to sperm donation for female couples and unmarried women. According to the Ministry of Health, since the opening of sperm donation to these new populations, requests at the national level (7000 during the first 6 months) have greatly exceeded the predicted figures (3000 per year). Welcoming this new patient population requires us, health professionals, to know it well. Indeed, to date, there is no reliable assessment in France of the life course, particularly reproductive, nor of the socio-demographic characteristics, nor of the psychological well-being of these patients. This study via a pseudonymised questionnaire aims to fill this lack of information in order to help professionals build relevant care pathways.

Official Title
-----------------
Access to Sperm Donation for Female Couples and Unmarried Women: First Descriptive Data at the Toulouse University Hospital. PLEIAD

Conditions
-----------------
Pregnancy Related

Intervention / Treatment
-----------------
* Other: Questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Heterosexual couples, OR couples of women OR single women who have requested a sperm donation at the Center for Reproductive Medicine at the Toulouse University Hospital Patients who have given their consent (oral or written) after clear and fair information Exclusion Criteria: First consultation with the centre's psychologist already carried out. Not fluent in French Protected adults (safeguard of justice, guardianship, curatorship)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Heterosexual couples, women or single women who have requested sperm donation<br>Heterosexual couples, female couples or single women who have requested a sperm donation in the center of the Toulouse University Hospital will be offered the study. | Other: Questionnaire<br>* A questionnaire is offered to patients who meet the eligibility criteria and who have given their non-objection before the first consultation with the centre's psychologist. This questionnaire includes questions on the socio-demographic characteristics, the motivations, as well as the procreative history of the patients.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Socio-demographic characteristics | Survey of socio-demographic characteristics of all persons eligible for sperm donation | Day 1 |
An Investigation Of The Relationship Between Temporomandibular Disorder With Posture And Pedobarographic Analysis

Study Overview
=================
Brief Summary
-----------------
The aim of the study is, to evaluate the whole body posture and plantar pressure distributions in individuals with Temporomandibular Disorder and also in people with healthy temporomandibular joints. A study group aged between 18-35 years, 30 patients, who were diagnosed with Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD) who applied us with jaw pain and 30 healthy people at the same age range as a control group were included in the study. Both groups received global postural assessments by using PostureScreen Mobile® (PSM) program which is using four side photographs and the New York Posture Scale (NYPS). Static pedobarographic measurements were taken.

Official Title
-----------------
Temporomandibular Rahatsızlığın Postür ve Pedobarografik Ölçüm Sonuçları Ile İlişkisinin Araştırılması

Conditions
-----------------
Temporomandibular Disorder

Intervention / Treatment
-----------------
* Other: Postural Analysis
* Other: plantar pressure analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: clinical diagnosis of Temporomandibular Diseases clinical diagnosis of healthy temporomandibular joint Exclusion Criteria: Trauma history Anatomic deformities and skeletal system fractures Orthopedic or rheumatic diseases diagnosed Pregnancy Having TMR treatment Being included in the physiotherapy program in the last 6 months

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: TMD Group<br>people who has TMD | Other: Postural Analysis<br>* posture and plantar pressure analysis<br>Other: plantar pressure analysis<br>* posture and plantar pressure analysis<br>|
| Other: Control Group<br>individuals who dont have healthy temporomandibular joint | Other: Postural Analysis<br>* posture and plantar pressure analysis<br>Other: plantar pressure analysis<br>* posture and plantar pressure analysis<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| flexion and extension degree | degree | 5 minutes | 
| translation | cm | 5 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| plantar pressure distribution | kPa | 2 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Plantar Pressure Distribution, Posture, Posturescreen Mobile, RDC/TMD, TMD